CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
嵌合抗原受体 (CAR) T 细胞治疗在 NHS 中的实施：前景、希望与隐患
英文原题：Implementation of chimeric antigen receptor (CAR) T-cell therapy in the NHS: prospects, promises and pitfalls.
查看英文原题
Implementation of chimeric antigen receptor (CAR) T-cell therapy in the NHS: prospects, promises and pitfalls.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法在英国NHS的批准、引入和提供，代表着癌症治疗与管理中一种创新且革命性的方法。CAR-T 细胞疗法是一种高度专业化且个性化的免疫治疗类型，通过合成修饰患者的T细胞，使其特异性靶向并消灭癌细胞，从而重新编程患者的免疫系统。该疗法有望治愈此前被认为无法治愈或对常规化疗难治的恶性肿瘤。然而，CAR-T 细胞疗法伴随显著风险和危及生命的并发症，并且需要巨额经济成本。CAR-T 细胞疗法在NHS的实施标志着个性化医疗的新时代，不仅为改善癌症结局提供了有前景的方法，也为提高晚期和复发性血液系统恶性肿瘤患者的生存率和生活质量提供了有前景的方法。
展开英文摘要原文
The approval, introduction, and provision of chimeric antigen receptor (CAR) T-cell therapy in the UK NHS presents a innovative and revolutionary approach in cancer treatment and management. CAR T-cell therapy is a highly specialised and personalised type of immunotherapy that involves reprogramming a patient's immune system by synthetically modifying their T-cells to specifically target and eliminate cancer cells. This therapy offers the potential to cure malignancies that were previously deemed incurable or refractory to conventional chemotherapy.
CAR T-cell therapy, however, is associated with significant risks and life-threatening complications, and it entails substantial financial cost. The implementation of CAR T-cell therapy in the NHS marks a new era of personalised medicine, offering a promising approach not only for improving cancer outcomes, but for enhancing survivorship and quality of life among patients with advanced and relapsing haematologic malignancies.
论文信息
- 作者
- Cajanding RJM
- 单位
- Senior Charge Nurse, Adult Critical Care Unit, St Bartholomew's Hospital, Barts Health NHS Trust, London.United Kingdom
- 期刊
- British journal of nursing (Mark Allen Publishing)2025 Mar 6
- 原文标识
- PubMed 40063539 · DOI 10.12968/bjon.2024.0056